NCT06795373View on ClinicalTrials.gov

Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Chronic Spontaneous UrticariaCSU
Interventions
DRUG

Ritlecitinib

Once daily dose of 100mg of ritlecitinib taken orally for 12 weeks

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Ahuva D Cices

OTHER

NCT06795373 - Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter